fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

Nucala is the first and only anti-IL-5 add-on treatment approved in Canada that targets eosinophilic inflammation in adults with chronic rhinosinusitis with nasal polyps – GSK

Written by | 2 Jan 2022 | ENT

Nucala (mepolizumab) is now approved in Canada as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled by intranasal corticosteroids alone. This is the fourth approved indication for Nucala for Canadian patients with eosinophilic driven diseases and is the first and only anti-IL-5 add-on treatment that targets eosinophilic inflammation in adults with CRSwNP.

“As the first anti-IL-5 for Canadians living with chronic rhinosinusitis with nasal polyps, this Nucala approval is an important new treatment option, particularly for patients with severe CRSwNP ( chronic rhinosinusitis with nasal polyps) who may have previously relied on oral steroids and recurrent surgery to manage their condition,” said Marni Freeman, Country Medical Director at GSK Canada. “With more than 50 years experience in developing and manufacturing respiratory medicines, we’re proud of this new indication as it represents yet another treatment option to address the unmet medical needs of patients living with eosinophilic driven diseases.”</p.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.